BALANCE Model: Medicare's GLP-1 Expansion Timeline

The BALANCE Model expands Medicare GLP-1 coverage starting in 2026, with the 71% price negotiation layering on top in 2027. Here's the full implementation timeline.

The BALANCE (Bundled Approach for Lasting Action Now and in Continuous Effort) Model is a CMS demonstration program announced in December 2025 that substantially expands Medicare coverage of GLP-1 medications for obesity and related metabolic conditions. Combined with the separate 71% Medicare semaglutide price negotiation effective January 2027, BALANCE represents the largest federal expansion of GLP-1 access in the program's history.

This timeline walks through what BALANCE actually is, what it covers, when its components take effect, and how beneficiaries can access the expanded benefits.

What BALANCE Is and Isn't

BALANCE is a CMS Innovation Center demonstration model — a structured program to test alternative payment and coverage approaches within Medicare. It is not a permanent change to Medicare law; it operates under CMS's statutory authority to test innovative models. Participating providers, plans, and patients operate under BALANCE-specific rules for the duration of the demonstration.

The core BALANCE concept is bundled, outcomes-oriented coverage of obesity-related care, including GLP-1 medications, dietary counseling, exercise support, behavioral health services, and coordinated care across providers. The bundle is designed to improve coordination and outcomes beyond what fragmented fee-for-service coverage delivers, and to make expanded GLP-1 coverage financially sustainable for the Medicare program.

Coverage Expansion Under BALANCE

Timeline of Implementation

The BALANCE Model rolls out in phases. The announcement in December 2025 set the strategic direction. Participating plans and Medicare Advantage organizations began onboarding in early 2026. Initial patient enrollment opens in mid-2026, with broader enrollment through the remainder of the year. The 71% semaglutide price negotiation, which is a separate but complementary program, takes effect January 1, 2027. The BALANCE bundle and negotiated pricing together will define the Medicare GLP-1 experience in 2027 and beyond.

How BALANCE Interacts with the Price Negotiation

The two programs are coordinated. BALANCE sets the coverage and care-bundle framework; the 71% discount sets the drug acquisition cost. A beneficiary enrolled under BALANCE receiving semaglutide for qualifying indications will have the drug acquisition cost at the negotiated Maximum Fair Price, with Part D cost-sharing determining the patient copay. The combined effect is that semaglutide access under Medicare for obesity-related conditions becomes meaningfully more affordable for both the program and the beneficiary starting in 2027.

Who Is Eligible

BALANCE eligibility is expected to focus on Medicare beneficiaries with obesity and qualifying comorbidities, enrolled in participating plans or care networks. Not every Medicare beneficiary will be eligible — the demonstration is structured to include specific participating plans and provider networks rather than blanket coverage for all Part D enrollees. Beneficiaries interested in BALANCE coverage should check with their Medicare Advantage plan or their Part D plan about participation.

What BALANCE Does Not Do

BALANCE does not cover GLP-1s for cosmetic weight loss, for patients without qualifying comorbidities, or outside the participating-plan framework. It does not override Part D cost-sharing structures. It does not extend automatically to tirzepatide (which has its own coverage considerations and will be eligible for future Medicare negotiation cycles). And as a demonstration, BALANCE is designed to test outcomes over a multi-year period; extension or permanent adoption depends on CMS's evaluation findings.

The Broader Federal GLP-1 Picture

BALANCE, the Medicare price negotiation, TrumpRx, and ongoing HRSA 340B access together form a much more expansive federal GLP-1 infrastructure than existed even 18 months ago. The combined impact on access for lower-income, elderly, and underinsured populations is substantial — though uneven, with access still constrained by geography, plan participation, and clinical eligibility criteria. For related reporting, see our Medicare 71% discount analysis and TrumpRx explainer.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.